TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open Label, Randomized, Multi-Center, Phase IIIB, Parallel Group Switching Study to Compare the Efficacy and Safety of Lipid Lowering Agents Atorvastatin and Simvastatin With Rosuvastatin in High Risk Subjects With Type IIa and IIb Hypercholesterolemia.
Brief Summary: The purpose of this study is to determine whether treatment with rosuvastatin following atorvastatin or simvastatin treatment will improve health outcomes for patients at high risk of Coronary heart disease compared to atorvastatin and simvastatin alone.


Options:
A: Arm Label: Pitavastatin; Type: EXPERIMENTAL; Interventions: Drug: Pitavastatin | Arm Label: Atorvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin | Intervention Type: DRUG; Name: Pitavastatin; Assigned to Arm(s): Pitavastatin | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Atorvastatin
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550, Drug: Atorvastatin | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550, Drug: Atorvastatin Placebo | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: Atorvastatin Placebo; Assigned to Arm(s): Arm 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Rosuvastatin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Simvastatin | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): 3
D: Arm Label: atorvastatin arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: atorvastatin | Arm Label: Lovaza arm; Type: EXPERIMENTAL; Interventions: Drug: Lovaza (omega-3-acid ethyl esters) [formerly known as Omacor] plus atorvastatin | Intervention Type: DRUG; Name: Lovaza (omega-3-acid ethyl esters) [formerly known as Omacor] plus atorvastatin; Assigned to Arm(s): Lovaza arm | Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): atorvastatin arm

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open Label, Randomized, Multi-Center, Phase IIIB, Parallel Group Switching Study to Compare the Efficacy and Safety of Lipid Lowering Agents Atorvastatin and Simvastatin With Rosuvastatin in High Risk Subjects With Type IIa and IIb Hypercholesterolemia.
Brief Summary: The purpose of this study is to determine whether treatment with rosuvastatin following atorvastatin or simvastatin treatment will improve health outcomes for patients at high risk of Coronary heart disease compared to atorvastatin and simvastatin alone.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: ABT-335 and rosuvastatin calcium | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: ABT-335 and atorvastatin calcium | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Drug: ABT-335 and simvastatin | Intervention Type: DRUG; Name: ABT-335 and rosuvastatin calcium; Assigned to Arm(s): A | Intervention Type: DRUG; Name: ABT-335 and atorvastatin calcium; Assigned to Arm(s): B | Intervention Type: DRUG; Name: ABT-335 and simvastatin; Assigned to Arm(s): C
B: Arm Label: rosuva 5; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rosuvastatin | Arm Label: rosuva 10; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rosuvastatin | Arm Label: rosuva 20; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rosuvastatin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: rosuva ol; Type: OTHER; Interventions: Drug: Rosuvastatin | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): rosuva 10, rosuva 20, rosuva 5, rosuva ol | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: ABT-335 and Rosuvastatin Calcium; Type: EXPERIMENTAL; Interventions: Drug: ABT-335 and rosuvastatin calcium | Arm Label: ABT-335; Type: ACTIVE_COMPARATOR; Interventions: Drug: ABT-335 | Arm Label: Rosuvastatin Calcium; Type: ACTIVE_COMPARATOR; Interventions: Drug: rosuvastatin calcium | Intervention Type: DRUG; Name: ABT-335 and rosuvastatin calcium; Assigned to Arm(s): ABT-335 and Rosuvastatin Calcium | Intervention Type: DRUG; Name: ABT-335; Assigned to Arm(s): ABT-335 | Intervention Type: DRUG; Name: rosuvastatin calcium; Assigned to Arm(s): Rosuvastatin Calcium
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Rosuvastatin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Simvastatin | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): 3

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Exercise Rehabilitation of Younger and Older People With Claudication
Brief Summary: The purpose of this study is to examine the effect of age and the effect of exercise intensity of rehabilitation programs on claudication pain symptoms and leg circulation of younger and older patients with intermittent claudication.


Options:
A: Arm Label: Strength training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Strength Training | Arm Label: Walking training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Walking Training | Intervention Type: BEHAVIORAL; Name: Walking Training; Assigned to Arm(s): Walking training | Intervention Type: BEHAVIORAL; Name: Strength Training; Assigned to Arm(s): Strength training
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Walking Exercise | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Walking Exercise | Intervention Type: BEHAVIORAL; Name: Walking Exercise; Assigned to Arm(s): 1, 2
C: Intervention Type: PROCEDURE; Name: Exercise therapy; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Accelerometer (PAM; Personal Activity Monitor); Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Oral Exercise Therapy advise; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Diet | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: Diet; Assigned to Arm(s): 3

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Exercise Rehabilitation of Younger and Older People With Claudication
Brief Summary: The purpose of this study is to examine the effect of age and the effect of exercise intensity of rehabilitation programs on claudication pain symptoms and leg circulation of younger and older patients with intermittent claudication.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supervised Exercise Therapy, Drug: Cilostazol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: Stent, Drug: Cilostazol | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Device: Stent, Behavioral: Supervised Exercise Therapy | Intervention Type: DEVICE; Name: Stent; Assigned to Arm(s): 2, 3 | Intervention Type: BEHAVIORAL; Name: Supervised Exercise Therapy; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: Cilostazol; Assigned to Arm(s): 1, 2
B: Arm Label: Intermittent claudication; Type: N/A; Interventions: N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Walking Exercise | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Walking Exercise | Intervention Type: BEHAVIORAL; Name: Walking Exercise; Assigned to Arm(s): 1, 2
D: Intervention Type: BEHAVIORAL; Name: Physical Activity; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel Group Study to Determine the Safety, Pharmacokinetics, and Effectiveness of LDP-02 in Patients With Mildly to Moderately Active Crohn's Disease
Brief Summary: The objectives of this study were to assess the safety and tolerability of LDP-02 in patients with active Crohn's disease who were not receiving corticosteroids or immunosuppressives, to assess the ability of LDP-02 to reduce Crohn's disease activity, and to obtain pharmacokinetic (PK) and pharmacodynamic(PD)information for LDP-02 in patients with active Crohn's disease.


Options:
A: Arm Label: Induction Phase: Vedolizumab, 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Vedolizumab | Arm Label: Induction Phase: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vedolizumab placebo | Arm Label: Maintenance Phase: Vedolizumab 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Vedolizumab | Arm Label: Maintenance Phase: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vedolizumab placebo | Arm Label: Maintenance Phase: Placebo Continuation; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vedolizumab placebo | Arm Label: Open-Label: Vedolizumab 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Vedolizumab | Intervention Type: DRUG; Name: Vedolizumab; Assigned to Arm(s): Induction Phase: Vedolizumab, 300 mg, Maintenance Phase: Vedolizumab 300 mg, Open-Label: Vedolizumab 300 mg | Intervention Type: DRUG; Name: Vedolizumab placebo; Assigned to Arm(s): Induction Phase: Placebo, Maintenance Phase: Placebo, Maintenance Phase: Placebo Continuation
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: infliximab+azathioprine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: methylprednisolone or budesonide | Intervention Type: DRUG; Name: infliximab+azathioprine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: methylprednisolone or budesonide; Assigned to Arm(s): 2
C: Arm Label: Vedolizumab; Type: EXPERIMENTAL; Interventions: Drug: vedolizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: vedolizumab; Assigned to Arm(s): Vedolizumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: LDP-02 | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: LDP-02 | Intervention Type: DRUG; Name: LDP-02; Assigned to Arm(s): 2, 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Neuroscience-Guided Cognitive Remediation in Adolescents at Risk for Psychosis
Brief Summary: This study will evaluate the effectiveness of intensive computerized cognitive training in preventing the onset of psychotic disorder and improving adaptive functioning in adolescents at high risk of schizophrenia.


Options:
A: Arm Label: Posit Science; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Remediation | Arm Label: Nintendo Brain Age; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Nintendo Brain Age | Intervention Type: BEHAVIORAL; Name: Cognitive Remediation; Assigned to Arm(s): Posit Science | Intervention Type: BEHAVIORAL; Name: Nintendo Brain Age; Assigned to Arm(s): Nintendo Brain Age
B: Arm Label: Experimental Treatment; Type: EXPERIMENTAL; Interventions: Other: Computerized plasticity-based adaptive cognitive training | Arm Label: Active Comparator; Type: ACTIVE_COMPARATOR; Interventions: Other: Commercially available computerized training | Intervention Type: OTHER; Name: Computerized plasticity-based adaptive cognitive training; Assigned to Arm(s): Experimental Treatment | Intervention Type: OTHER; Name: Commercially available computerized training; Assigned to Arm(s): Active Comparator
C: Arm Label: Targeted Cognitive Training; Type: EXPERIMENTAL; Interventions: Other: Targeted Cognitive Training | Arm Label: Social Cognitive Training; Type: EXPERIMENTAL; Interventions: Other: Social Cognitive Training | Intervention Type: OTHER; Name: Targeted Cognitive Training; Assigned to Arm(s): Targeted Cognitive Training | Intervention Type: OTHER; Name: Social Cognitive Training; Assigned to Arm(s): Social Cognitive Training
D: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Computer games | Arm Label: Active; Type: EXPERIMENTAL; Interventions: Behavioral: Neuroadaptive cognitive training | Arm Label: Healthy Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Neuroadaptive cognitive training | Intervention Type: BEHAVIORAL; Name: Neuroadaptive cognitive training; Assigned to Arm(s): Active, Healthy Control | Intervention Type: BEHAVIORAL; Name: Computer games; Assigned to Arm(s): Control

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Neuroscience-Guided Cognitive Remediation in Adolescents at Risk for Psychosis
Brief Summary: This study will evaluate the effectiveness of intensive computerized cognitive training in preventing the onset of psychotic disorder and improving adaptive functioning in adolescents at high risk of schizophrenia.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: glycine | Intervention Type: DRUG; Name: glycine; Assigned to Arm(s): 1
B: Arm Label: BI 409306; Type: EXPERIMENTAL; Interventions: Drug: BI 409306 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: BI 409306; Assigned to Arm(s): BI 409306 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Computer games | Arm Label: Active; Type: EXPERIMENTAL; Interventions: Behavioral: Neuroadaptive cognitive training | Arm Label: Healthy Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Neuroadaptive cognitive training | Intervention Type: BEHAVIORAL; Name: Neuroadaptive cognitive training; Assigned to Arm(s): Active, Healthy Control | Intervention Type: BEHAVIORAL; Name: Computer games; Assigned to Arm(s): Control
D: Arm Label: Family Focused Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Family Focused Treatment | Arm Label: Enhanced Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced Care | Intervention Type: BEHAVIORAL; Name: Family Focused Treatment; Assigned to Arm(s): Family Focused Treatment | Intervention Type: BEHAVIORAL; Name: Enhanced Care; Assigned to Arm(s): Enhanced Care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: GvHD Prophylaxis With ATG-Fresenius S in Allogeneic Stem Cell Transplantation From Matched Unrelated Donors: A Randomized Phase III Multicenter Trial Comparing a Standard GvHD Prophylaxis With Cyclosporine A and Methotrexate With Additional Pretransplant ATG-Fresenius S
Brief Summary: The study aim is to evaluate the influence of the anti-T-lymphocyte globulin ATG-Fresenius S given pre-transplant in addition to standard GvHD prophylaxis with cyclosporine A and a short course of methotrexate with respect to efficacy and safety.


Options:
A: Arm Label: ATG combined regimen; Type: EXPERIMENTAL; Interventions: Drug: ATG, Drug: CsA, Drug: mycophenolate mofetil, Drug: Methotrexate | Arm Label: no-ATG; Type: ACTIVE_COMPARATOR; Interventions: Drug: CsA, Drug: mycophenolate mofetil, Drug: Methotrexate | Intervention Type: DRUG; Name: ATG; Assigned to Arm(s): ATG combined regimen | Intervention Type: DRUG; Name: CsA; Assigned to Arm(s): ATG combined regimen, no-ATG | Intervention Type: DRUG; Name: mycophenolate mofetil; Assigned to Arm(s): ATG combined regimen, no-ATG | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): ATG combined regimen, no-ATG
B: Arm Label: routine prophylaxis; Type: ACTIVE_COMPARATOR; Interventions: Drug: anti thymoglobulin | Arm Label: ATG prophylaxis; Type: EXPERIMENTAL; Interventions: Drug: anti thymoglobulin | Intervention Type: DRUG; Name: anti thymoglobulin; Assigned to Arm(s): ATG prophylaxis, routine prophylaxis
C: Arm Label: ATG 7.5mg/kg; Type: EXPERIMENTAL; Interventions: Drug: ATG | Arm Label: ATG 10mg/kg; Type: EXPERIMENTAL; Interventions: Drug: ATG | Intervention Type: DRUG; Name: ATG; Assigned to Arm(s): ATG 10mg/kg, ATG 7.5mg/kg
D: Arm Label: ATG-F; Type: EXPERIMENTAL; Interventions: Drug: ATG-Fresenius S | Arm Label: non-ATG-F; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: ATG-Fresenius S; Assigned to Arm(s): ATG-F

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Proof-of-concept Study to Evaluate the Benefit From add-on Therapy With Montelukast Versus Salmeterol in Children With Asthma Carrying the Arg/Arg-16 beta2-receptor Genotype
Brief Summary: The purpose of this study is to determine whether patients with asthma who carry a genotype associated with adverse outcomes with long-acting beta-2 agonists like salmeterol show greater benefit from the use of an asthma drug that works via alternative pathways like montelukast.


Options:
A: Arm Label: 1 Budesonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Budesonide | Arm Label: 2 Nedocromil; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nedocromil | Arm Label: 3 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3 Placebo | Intervention Type: DRUG; Name: Nedocromil; Assigned to Arm(s): 2 Nedocromil | Intervention Type: DRUG; Name: Budesonide; Assigned to Arm(s): 1 Budesonide
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol, Montelukast | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Montelukast Placebo | Intervention Type: DRUG; Name: Montelukast Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Salmeterol, Montelukast; Assigned to Arm(s): 1
C: Arm Label: Fluticasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluticasone, Drug: montelukast, Drug: Fluticasone plus salmeterol | Arm Label: Montelukast; Type: EXPERIMENTAL; Interventions: Drug: fluticasone, Drug: montelukast, Drug: Fluticasone plus salmeterol | Arm Label: Fluticasone plus salmeterol; Type: EXPERIMENTAL; Interventions: Drug: fluticasone, Drug: montelukast, Drug: Fluticasone plus salmeterol | Intervention Type: DRUG; Name: fluticasone; Assigned to Arm(s): Fluticasone, Fluticasone plus salmeterol, Montelukast | Intervention Type: DRUG; Name: montelukast; Assigned to Arm(s): Fluticasone, Fluticasone plus salmeterol, Montelukast | Intervention Type: DRUG; Name: Fluticasone plus salmeterol; Assigned to Arm(s): Fluticasone, Fluticasone plus salmeterol, Montelukast
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone propionate/Formoterol fumarate 250/10 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone propionate/Formoterol fumarate 100/10 | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone propionate 250 | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol fumarate 10 | Arm Label: 5; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fluticasone propionate/Formoterol fumarate 250/10; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 5 | Intervention Type: DRUG; Name: Fluticasone propionate/Formoterol fumarate 100/10; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Fluticasone propionate 250; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Formoterol fumarate 10; Assigned to Arm(s): 4

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Proof-of-concept Study to Evaluate the Benefit From add-on Therapy With Montelukast Versus Salmeterol in Children With Asthma Carrying the Arg/Arg-16 beta2-receptor Genotype
Brief Summary: The purpose of this study is to determine whether patients with asthma who carry a genotype associated with adverse outcomes with long-acting beta-2 agonists like salmeterol show greater benefit from the use of an asthma drug that works via alternative pathways like montelukast.


Options:
A: Arm Label: Fluticasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluticasone, Drug: montelukast, Drug: Fluticasone plus salmeterol | Arm Label: Montelukast; Type: EXPERIMENTAL; Interventions: Drug: fluticasone, Drug: montelukast, Drug: Fluticasone plus salmeterol | Arm Label: Fluticasone plus salmeterol; Type: EXPERIMENTAL; Interventions: Drug: fluticasone, Drug: montelukast, Drug: Fluticasone plus salmeterol | Intervention Type: DRUG; Name: fluticasone; Assigned to Arm(s): Fluticasone, Fluticasone plus salmeterol, Montelukast | Intervention Type: DRUG; Name: montelukast; Assigned to Arm(s): Fluticasone, Fluticasone plus salmeterol, Montelukast | Intervention Type: DRUG; Name: Fluticasone plus salmeterol; Assigned to Arm(s): Fluticasone, Fluticasone plus salmeterol, Montelukast
B: Intervention Type: BEHAVIORAL; Name: Shared-Decision Making; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol, Montelukast | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Montelukast Placebo | Intervention Type: DRUG; Name: Montelukast Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Salmeterol, Montelukast; Assigned to Arm(s): 1
D: Arm Label: Placebo pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Singular pill; Type: EXPERIMENTAL; Interventions: Drug: singular | Intervention Type: DRUG; Name: singular; Assigned to Arm(s): Singular pill | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo pill

Answer: C